This is a summary of the European public assessment report (EPAR) for Cetrotide. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cetrotide.
Cetrotide : EPAR - Medicine overview (PDF/123.02 KB)
First published: 24/11/2009
Last updated: 19/12/2019
|Agency product number||
cetrorelix (as acetate)
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Merck Europe B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Gustav Mahlerplein 102
30/08/2019 Cetrotide - EMEA/H/C/000233 - IAIN/0072
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pituitary and hypothalamic hormones and analogues
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte-pick-up and assisted-reproductive techniques.